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Abstract
Background
Irritable bowel syndrome (IBS) and functional digestive tract disorders, e.g. functional bloat-
ing, carbohydrate maldigestion and intolerances, are very common disorders frequently
causing significant symptoms that challenge health care systems. A low Fermentable Oligo-
saccharides, Disaccharides, Monosaccharides and Polyols (FODMAP) diet is one of the
possible therapeutic approaches for decreasing abdominal symptoms and improving quality
of life.
Objectives
We aimed to meta-analyze data on the therapeutic effect of a low-FODMAP diet on symp-
toms of IBS and quality of life and compare its effectiveness to a regular, standard IBS diet
with high FODMAP content, using a common scoring system, the IBS Symptom Severity
Score (IBS-SSS).
Methods
A systematic literature search was conducted in PubMed, EMBASE and the Cochrane
Library as well as in the references in a recent meta-analysis. Adult patients diagnosed with
IBS according to the Rome II, Rome III, Rome IV or NICE criteria were included in the
analysis.
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Statistical methods
Mean differences with 95% confidence intervals were calculated from studies that contained
means, standard deviation (SD) or mean differences and SD of differences and p-values. A
random effect model was used because of the heterogeneity (Q test (χ2) and I2 indicator). A
p-value of less than 0.05 was chosen to indicate a significant difference.
Results
The literature search yielded 902 publications, but only 10 were eligible for our meta-analy-
sis. Both regular and low-FODMAP diets proved to be effective in IBS, but post-diet IBS-
SSS values were significantly lower (p = 0.002) in the low-FODMAP group. The low-FOD-
MAP diet showed a correlation with the improvement of general symptoms (by IBS-SSS) in
patients with IBS.
Conclusions
This meta-analysis provides high-grade evidence of an improved general symptom score
among patients with irritable bowel syndrome who have maintained a low-FODMAP diet
compared to those on a traditional IBS diet, therefore showing its superiority to regular IBS
dietary therapy. These data suggest that a low-FODMAP diet with dietitian control can be a
candidate for first-line therapeutic modality in IBS. Because of a lack of data, well-planned
randomized controlled studies are needed to ascertain the correlation between improve-
ment of separate key IBS symptoms and the effect of a low-FODMAP diet.
Introduction
Irritable bowel syndrome (IBS) is a common chronic functional gastrointestinal disorder,
which can be defined by the Rome IV criteria [1, 2]. IBS causes abdominal pain or discomfort,
bloating and altered bowel habits (diarrhoea, constipation or a combination of these), without
any pathological abnormality of the intestinal wall [3]. It can lead to significant impairment of
quality of life (e.g. social isolation or stigmatization [4, 5]), decreased work productivity and an
increase of health care and societal costs [6–9]. The incidence of the disease is high in Western
countries, affecting 10–20% of the adult population, and it is twice more common among
women [10, 11]. The exact pathomechanism remains unclear, but visceral hypersensitivity,
altered gastrointestinal motility, changes in gut microbiota, altered brain–gut axis, low-grade
digestive tract inflammation and psychological factors may play a role [12–14]. Because of the
uncertain aetiology and pathophysiology, only a few effective, non-specific treatment options
exist, improving only some key symptoms but not leading to the healing of IBS (laxatives, anti-
diarrhoeal agents, antispasmodics, antidepressants, and dietary and psychiatric interventions)
[8, 15, 16]. Treatment is often multimodal, comprising dietary, psychological and pharmaco-
logical methods [15]. Several studies have proven that certain foods worsen the symptoms in
most IBS patients because they play an important role in the development of those symptoms
[17–23]. The most commonly reported foods are those containing lactose (milk, ice cream and
yogurt) or fructose (honey, dates, oranges, cherries, apples and pears), gas-producing foods
(beans, peas, broccoli, cabbage and bran), wheat and wheat-containing products, and sweeten-
ers (sorbitol, mannitol and xylitol) [18]. These findings suggest that dietary intervention that
Low-FODMAP diet improves IBS symptoms: A meta-analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0182942 August 14, 2017 2 / 15
Abbreviations: CI, Confidence interval; DIM,
Difference in means; ES, Effect Size; Fig, Figure;
FODMAP, Fermentable Oligosaccharides,
Disaccharides, Monosaccharides and Polyols; GI,
Gastrointestinal; IBD, Inflammatory bowel disease;
IBS, Irritable bowel syndrome; IBS-SSS, Irritable
Bowel Syndrome Symptom Severity Score;
MINORS, Methodological Index for Non-
Randomized Studies; mm, millimetre; NICE,
National Institute for Health and Care Excellence;
PICO, Population/Problem, Intervention,
Comparison, Outcome; PRISMA-P, Preferred
Reporting Items for Systematic Review and Meta-
Analysis Protocol; RCT, Randomized controlled
trial; SD, Standard deviation; s.e., Standard error;
S/Suppl., Supplementary material; VAS, Visual
Analogue Scale.
excludes symptom-triggering food components could be a promising treatment option for
IBS. Standard dietary interventions are detailed in some guidelines, e.g. the British Dietary
Association and NICE guidelines [24, 25]. They recommend that patients regularly eat three
meals and three snacks a day, never too much or too little, eat in peace and quiet, chew thor-
oughly, avoid certain foods (e.g. fatty or spicy foods, alcohol, coffee, onions, cabbage, beans,
carbonated beverages, etc.) and eat fibre but distribute its intake over the day. A suggested
main dietary approach is increased daily fibre intake; however, while improving general IBS
symptoms in some subgroups, it can worsen them in others [26–29]. Reduction of dietary fat
intake improved symptoms in patients because fatty acids can trigger symptoms in IBS [20,
23]. The effect of a gluten-exclusion diet is also controversial [30, 31]. A novel treatment option
is a diet low in FODMAPs (Fermentable Oligosaccharides, Disaccharides, Monosaccharides
and Polyols). Many popular, healthy foods have a high-FODMAP content, such as fruits
(apples, pears, peaches and watermelons), vegetables (onions, garlic, squash and mushrooms),
dairy products, grains (wheat and rye), and sweeteners (sorbitol and mannitol), etc. [32]. FOD-
MAPs can trigger symptoms in IBS patients, based on two major mechanisms [8, 33–37]. The
‘small bowel hypothesis’ states that FODMAPs are unabsorbed, osmotically active molecules
(carbohydrates), so they increase the intraluminal water content in the small intestine. This
leads to distension, which causes symptoms such as bloating and discomfort. The increased
distension also leads to faster oro-cecal transit, which impairs absorption in the small bowel
[36]. The second mechanism (‘large bowel hypothesis’) describes FODMAPs reaching the
colon unabsorbed, where they are rapidly fermented by colonic bacteria. This causes flatu-
lence, bloating and discomfort through increased gas production and distension of the colonic
wall [36]. Because of visceral hypersensitivity, the same magnitude of distension will produce
different degrees of symptoms, depending on individual susceptibility [38]. These findings
suggested that the exclusion of FODMAPs from the diet could improve IBS symptoms. A
growing number of studies have shown a positive effect of FODMAPs on IBS symptoms. The
need has thus arisen for a meta-analysis with a focus on effectiveness to provide evidence and
underpin recommendations for wider therapeutic use. Our aim was to carry out a meta-analy-
sis to prove whether a low-FODMAP diet improves the symptoms of adult IBS patients more
effectively than other (standard) dietary interventions (i.e. without restriction of FODMAP
content) recommended by the latest guidelines. Following the PRISMA 2009 guidelines, we
used the PICO format to formulate our question (P: patients with IBS; I: low-FODMAP diet;
C: high-FODMAP/standard IBS diet; O: IBS Symptom Severity Score (IBS-SSS)).
Methods
Search for articles
Our work was planned according to the PRISMA 2009 statement (S1 File). A systematic litera-
ture search was conducted by two independent reviewers (JC and PV) to find relevant articles
on the effect of low-FODMAP dietary intervention in IBS up to 19 September 2016. The search
covered three databases (PubMed, EMBASE and the Cochrane Library) with the terms ‘FOD-
MAP AND irritable bowel syndrome’. For better targeting of synonymous phrases, we used
the search terms: ‘FODMAP’ OR ‘FODMAPS’ OR ‘Fermentable poorly absorbed short chain
carbohydrates’ OR ‘Fermentable oligosaccharides disaccharides monosaccharides and polyols’
as was done in a recent meta-analysis by Marsh et al. [39]. After this search process, language
(only English) and species (only humans) filters were used and a title, and abstract screening
was performed by the reviewers to identify potentially eligible articles. Disagreements were
resolved by discussion. Duplicates were removed.
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Study selection
We included randomized controlled trials (RCT), non-randomized controlled trials and non-
controlled prospective trials in our meta-analysis. Retrospective studies were excluded. The
length of follow-up was not a reason for either inclusion or exclusion. Only articles written in
English and those examining the effect of a low-FODMAP diet in human IBS patients were
included in the meta-analysis. By definition, adult IBS patients (18 years or above) had to be
diagnosed according to the Rome II, Rome III, Rome IV or NICE criteria. We enrolled con-
trolled studies which included adult IBS patients as a control group. In the control groups, IBS
patients had to follow a standard IBS diet (according to the guidelines) with significantly
higher FODMAP content than in the intervention (low-FODMAP) group. As a standard, vali-
dated output measure, we searched for studies reporting the IBS Symptom Severity Score
(IBS-SSS). The measurement of the severity of individual symptoms among the studies showed
great heterogeneity (e.g. Visual Analogue Scale, different types of Likert scale, etc.), so we used
only the complex IBS-SSS in our analysis as an outcome measure. Articles examining the
results of patients with an organic disease (for example, inflammatory bowel disease and IBD)
with functional gastrointestinal symptoms, which are similar to IBS symptoms, were excluded
from the analysis.
Quality assessment of the individual studies
The quality of RCTs was assessed with the frequently used Jadad score [40], while non-ran-
domized and non-controlled prospective studies were evaluated according to the Methodolog-
ical Index for Non-Randomized Studies (MINORS) [41]. Both scores were evaluated by JC
and PV. Any disagreements were resolved by consensus.
Data extraction
At the end of the screening process, relevant data were independently extracted from studies
by the two reviewers (JC and PV). These included: IBS-SSS as the main outcome parameter,
study design (e.g. randomized controlled trials, non-randomized controlled trials, etc.), basic
characteristics of the study population (age, percentage of females and IBS subtypes), length of
follow-up, diagnostic criteria for IBS and the size of the low-FODMAP and control (high-
FODMAP) groups. Extracted data were validated by five co-authors (AG, IS, GP, A´V and A´S).
Outcome measure
IBS-Symptom Severity Score (IBS-SSS). This score provides a measure of overall IBS
severity. It was validated by Francis et al. [42] in 1997 and consists of five questions that mea-
sure abdominal pain severity, abdominal pain frequency, abdominal bloating, bowel habit dis-
satisfaction and interference with quality of life on a 100 mm visual analogue scale (VAS).
Patients should rate every symptom with a score from 0–100, so the theoretical range is 0–500
mm, with higher scores indicating a more severe disease. A final score of less than 175 indi-
cates mild IBS, 175–300 shows moderate IBS, and>300 points to severe IBS [39].
Statistical analysis
Data analysis was conducted with the Comprehensive Meta-Analysis software (Version 3.0,
Biostat Inc.). In the forest plot analysis, mean differences with 95% confidence intervals were
calculated from studies that contained means, standard deviation (SD) or mean differences
and SD of differences and p-values. In one study (Pedersen et al. [43]), where the results were
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expressed as median, minimum and maximum values, we converted the data using the Hozo
method [44].
The studies we included in the meta-analysis indicated that there is a considerable heteroge-
neity (different clinical methods, diverse participants, etc.), so the random effects model was
used according to the DerSimonian and Laird method [45]. Statistically, heterogeneity was
tested by Q test (χ2) and I2 indicator [46]. I2 indicator and Q tests were performed to assess
whether the heterogeneity observed among effect sizes could be attributed to random chance
or if other factors may play a role. The similar effect of non-investigated variables such as food
intolerances and functional digestive tract disorders other than IBS could also cause IBS-like
symptoms. I2 statistics represent the percentage of effect size heterogeneity that cannot be
explained by random chance, but by other factors noted above. If the Q test is significant, it
implies that the heterogeneity among effect sizes reported in the studies selected is more
diverse than could be explained by random error only. The Q test was considered significant
when p< 0.1.
We used subgroup analysis, with a p-value of less than 0.05 indicating a significant differ-
ence to compare the differences in the IBS-SSS between the control and low-FODMAP diet
groups. Results from the meta-analysis were displayed graphically using forest plots. The
potential for “small study effects”, including publication bias, was examined by visual inspec-
tion of funnel plots, in which the standard error was plotted against the net change for each
study. In both funnel plots, an asymmetry could be observed, which could be caused by the
subgroups. In S1 Fig the subgroup analysis indicates some publication bias, but in S2 Fig the
same analysis suggests no such bias.
Results
Searching results
Using the terms above, we found 880 articles in the three databases for evaluation, 261 in
PubMed, 87 in the Cochrane Library and 532 in EMBASE. We also examined 22 further arti-
cles from the recent meta-analysis noted above [39], so 902 articles were found in total. After
using the language (only English) and species (only humans) filters in EMBASE, PubMed and
the Cochrane Library, 673 of 880 studies remained, and one of 22 was excluded from the
meta-analysis by Marsh et al. [39] because it failed to meet the English-language inclusion cri-
terion. After title and abstract screening and removing duplicates, 10 articles reporting on
IBS-SSS eligible for further evaluation were found (Fig 1). Of these studies, 6 were available in
full-text format, and 4 were short abstracts or supplements. The number of controlled trials
was 7, and there were 3 non-controlled prospective studies. Of the controlled trials, 5 were ran-
domized controlled trials (RCT), and 2 were non-randomized studies. At the time of the litera-
ture search, we found no eligible paper that used the most recent diagnostic criteria (Rome IV)
for IBS. The basic characteristics of the articles are summarized in Table 1. The proportion of
each IBS subtype in the studies included in the meta-analysis is detailed in Table 2. A quality
assessment of the articles is summarized in Table 3.
Low-FODMAP and control diets
Patients received dietary advice from a dietitian on a low- or high-FODMAP diet in 7 [8, 16,
43, 47, 49, 51, 53] of the 10 studies analyzed. 2 [50, 52] abstracts included in the meta-analysis
failed to detail any information about dietitian involvement in the introduction of a low- or
high-FODMAP diet. In a study by Laatikainen et al. [48], a special low-FODMAP diet contain-
ing rye bread was prepared for the patients, which had been developed and supplied by a bak-
ery. Its FODMAP (fructan and mannitol) content was clearly lower than that of regular rye
Low-FODMAP diet improves IBS symptoms: A meta-analysis
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Fig 1. Flow chart for the systematic literature search.
https://doi.org/10.1371/journal.pone.0182942.g001
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Table 1. Baseline characteristics of the studies involved in the meta-analysis.
References Country Study design Study duration total or low-
FODMAP/control
cohort size
IBS diagnostic
criteria
Age (years) Percentage of
females (%)
Bo¨hn et al. [8] Sweden multi-centre, parallel,
randomized, controlled, single-
blind, comparative trial
4 weeks 33/34 Rome III low-FODMAP:
mean: 44 (18–69);
control: mean: 41
(18–68)
total: 81;
low-FODMAP:
79;
control: 84
McIntosh et al.
[47]
Canada prospective, randomized,
single-blind, parallel study
3 weeks 18/19 Rome III low- FODMAP:
mean: 50.28 (26–
77);
control: mean:
5147 (24–83)
total: 86;
low-FODMAP:
83;
control: 89
Pedersen et al.
(B) [16]
Denmark randomized, non-blind,
controlled trial
6 weeks 42/40 started, 34/
37 finished
Rome III low-FODMAP:
median: 37 (18–
71);
control: median:
32 (18–73)
total: 77;
low-FODMAP:
81;
control: 72.5
Laatikainen et al.
[48]
Finland randomized, double-blind, 2x2
cross-over study
13 weeks (1- week run-in, 2x4-
week intervention, 4 -week
wash-out period)
80 started, 73
finished
Rome III mean: 42.9 (21–
64)
91
Schultz et al.
(Suppl.) [49]
New
-Zealand
randomized controlled trial 12 weeks 23/27 Rome III no data no data
Pedersen et al.
(A) [43]
Denmark single-blind, cross-over
intervention
12 weeks (0–6 and 7–12
weeks)
19 Rome III median 35 (18–
74)
74
Piacentino et al.
(Suppl.) [50]
Italy prospective controlled trial 4 weeks 28/28 no data 21–68 68
Ones et al.
(Suppl.) [51]
Norway non-controlled prospective
study
6 weeks 23 Rome III mean: 35±11 87
Rossi et al.
(Suppl.) [52]
Italy non-controlled prospective
study
8 weeks 12 Rome III mean: 44.2±15.5 92
Valeur et al. [53] Norway non-controlled prospective
study
4 weeks 63 Rome III mean: 38.4 (19–
67)
89
FODMAP = Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols; IBS = Irritable Bowel Syndrome; Suppl. = Supplementary
material
https://doi.org/10.1371/journal.pone.0182942.t001
Table 2. The proportion of each IBS subtype in the studies included in the meta-analysis.
References IBS subtype
Low-FODMAP group (%) Control diet group (%)
Bo¨hn et al. IBS-D: 26; IBS-C: 24; IBS-M/U: 50 IBS-D: 22; IBS-C: 35; IBS-M/U: 43
McIntosh et al. IBS-D: 22; IBS-C: 6; IBS-M: 67;
IBS-U: 5
IBS-D: 32; IBS-C: 5; IBS-M: 58; IBS-U:
5
Pedersen et al. (B) IBS-D: 45; IBS-C: 12; IBS-M: 33;
IBS-U: 10
IBS-D: 45; IBS-C: 17.5; IBS-M: 35;
IBS-U: 2.5
Laatikainen et al. IBS-D: 32.5; IBS-M: 62.5; IBS-U: 5
Schultz et al. (Suppl.) no data no data
Pedersen et al. (A) IBS-D: 42; IBS-C: 21; IBS-A: 37
Piacentino et al.
(Suppl.)
no data no data
Ones et al. (Suppl.) no data -
Rossi et al. (Suppl.) IBS-D: 25; IBS-C: 17; IBS-M: 58 -
Valeur et al. IBS-D: 54; IBS-C: 16; IBS-M: 30 -
FODMAP = Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols; IBS = Irritable
Bowel Syndrome; IBS-D = IBS-Diarrhoeal subtype; IBS-C = IBS-Constipation subtype; IBS-M/
A = IBS-Mixed/Alternation subtype; IBS-U = IBS-Unsubtyped; Suppl. = Supplementary material. The
number of patients in each IBS subtype groups is expressed in S1 Table.
https://doi.org/10.1371/journal.pone.0182942.t002
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bread. The control group was not homogeneous among the studies, but it always had a signifi-
cantly higher FODMAP content. The precise content of the foods used was only detailed in 2
trials [8, 48]; the others probably followed dietary guidelines. This uncertainty could have
influenced our results.
IBS-SSS
First, we wanted to see if a low-FODMAP diet is an effective treatment for irritable bowel
syndrome. We compared the pre- vs. post-intervention IBS-SSS in control groups (4 publica-
tions) and low-FODMAP groups (8 publications) (Fig 2). There was a significant reduction in
IBS-SSS in both control (difference in means (DIM), post- minus pre-values: –59.816 (95% CI:
–108.922 ––10.710); p = 0.017) and low-FODMAP groups (DIM: –105.339 (95% CI: –140.773
––69.905); p = 0.000). This means that both standard (high-FODMAP) and low-FODMAP
diets are effective in improving symptoms and quality of life among IBS patients. The forest
plot suggests that a low-FODMAP diet is more effective, but we cannot prove this statistically
because of the overlapping confidence intervals. Significant heterogeneity was found between
the studies: control group IBS-SSS values: Q = 9.837; df = 3; p = 0.02; I2 = 69.504%; low-FOD-
MAP group IBS-SSS values: Q = 26.321; df = 7; p< 0.001; I2 = 73.405%.
We compared (Fig 3) the pre- and post-intervention scores between the control and low-
FODMAP groups in the controlled trials (6 publications for each group). This shows that there
is no statistically significant difference in pre-values between the groups (DIM: control minus
low-FODMAP values: –8.675 (95% CI: –40.043 –+22.693); p = 0.588), but a significant differ-
ence between post-values (DIM: +51.537 (95% CI: +18.891 –+84.183); p = 0.002) could be
observed. These results confirm that the therapeutic effect of a low-FODMAP diet is better
than standard dietary advice in patients with IBS. The meta-analysis also showed a significant
heterogeneity: pre-IBS-SSS values: Q = 21.242; df = 5; p = 0.001; I2 = 76.462; post-IBS-SSS val-
ues: Q = 20.675; df = 5; p = 0.001; I2 = 75.816.
Discussion
The standard dietary approach for IBS dietary therapy (e.g. high-fibre, low-fat, etc., as detailed
above) recommended by guidelines only improves IBS symptoms to a limited extent. A grow-
ing number of recent studies have shown a beneficial effect of a low-FODMAP diet on IBS
Table 3. Quality assessment of the studies included in the meta-analysis.
Study design Jadad score MINORS
Bo¨hn et al. multi-centre, parallel, randomized, controlled, single-blind, comparative trial 3/5 -
McIntosh et al. prospective, randomized, single-blind, parallel study 3/5 -
Pedersen et al. (B) Randomized, non-blind, controlled trial 3/5 -
Laatikainen et al. randomized, double-blind, 2x2 cross-over study 5/5 -
Schultz et al. (Suppl.) randomized controlled trial 0/5 -
Pedersen et al. (A) single-blind cross-over intervention - 16/24
Piacentino et al. (Suppl.) prospective controlled trial - 15/24
Ones et al. (Suppl.) non-controlled prospective study - 8/16
Rossi et al. (Suppl.) non-controlled prospective study - 9/16
Valeur et al. non-controlled prospective study - 12/16
Randomized controlled trials were evaluated with the Jadad score (0 = very poor, 5 = rigorous) [40]. Non-randomized studies were evaluated with the
MINORS (Methodological Index for Non-Randomized Studies) [41], in which 12 items are scored (0: not reported; 1: reported, but inadequate; 2: reported
and adequate). The global ideal score is 16 for non-comparative studies and 24 for comparative studies. Suppl. = Supplementary material.
https://doi.org/10.1371/journal.pone.0182942.t003
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symptoms. Several of them have compared its efficacy to a standard IBS diet and challenged us
to review the latest literature on the issue. A recent meta-analysis by Marsh et al. [39] analyzed
the beneficial effect of a low-FODMAP diet on symptoms and quality of life in adult and pedi-
atric patients with IBS and inflammatory bowel disease in the literature up to 24 March 2015.
They only investigated the complex IBS-SSS only in 4 articles, and it was not stated whether
low-FODMAP diet is significantly better than a control diet or not. We carried out our analysis
on IBS-SSS, using more (10) articles, and we only focused on adult patients with IBS. A
Fig 2. Forest plot of IBS-SSS DIMs, comparing pre- vs. post-intervention values within groups (low-FODMAP
and control). IBS-SSS = Irritable Bowel Syndrome Symptom Severity Score (0–500); DIM = Difference in Means;
FODMAP = Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols.
https://doi.org/10.1371/journal.pone.0182942.g002
Fig 3. Forest plot of IBS-SSS DIMs, comparing pre- and post-intervention values between groups (low-
FODMAP vs. control). IBS-SSS = Irritable Bowel Syndrome Symptom Severity Score (0–500); DIM = Difference in
Means; FODMAP = Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols.
https://doi.org/10.1371/journal.pone.0182942.g003
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previous meta-analysis by Khan et al. and systematic review by Rao et al. [32, 54] also proved
the efficacy of this diet on symptom improvement and suggested its introduction as a baseline
treatment, but they could not state clearly whether it is better than standard dietary advice or
not. Rao et al. [54] also investigated the high-fibre diet on chronic constipation and IBS. They
performed a literature search up to September 2014 and did not conduct a statistical analysis
due to heterogeneity and methodological quality. To our knowledge, this is the first meta-anal-
ysis to compare the effectiveness of low-FODMAP foods to a regular IBS diet recommended
by the guidelines.
A pooled analysis of 7 controlled trials (5 randomized and 2 non-randomized) and 3 non-
controlled trials confirmed that a low-FODMAP diet significantly improves general symptoms
(IBS-SSS) in patients with IBS compared to standard dietary recommendations and a high-
FODMAP diet. FODMAPs are poorly absorbed carbohydrates that cause an increase of water
content in the bowel based on the osmotic effect and increased gas production by colonic bac-
terial flora. These effects of FODMAPs induce several symptoms in patients with irritable
bowel syndrome and numerous patients with functional gastrointestinal disorders mainly by
distension and the osmotic laxative effect [8, 36, 37].
The pooled sample size was large, and the expression of the data from the studies enrolled
was acceptably homogeneous with regard to the key question of the meta-analysis.
Because of the considerable heterogeneity of the expressed data, the random effects model
was used with the DerSimonian and Laird [45] method for analysis. This is possible because of
the similar effect of non-investigated variables such as food intolerances and functional diges-
tive tract disorders other than IBS that could cause IBS-like symptoms as well. It would be
important to study the effect of a low-FODMAP diet in these groups to better understand the
role of a food challenge in provoking uncompliant symptoms of functional digestive tract dis-
orders, as in IBS. Nevertheless, the beneficial effects of a low-FODMAP diet on IBS-SSS were
statistically significant even in the heterogeneous population analyzed, thus supporting the
high impact of this diet on IBS symptoms.
Study data reflected some publication bias based on heterogeneity (S1 Fig) and no signifi-
cant bias based on time-based comparisons of the low-FODMAP diet (S2 Fig).
We evaluated the quality of the studies included in the meta-analysis (Table 2, S2 Table)
using the Jadad score for RCTs and MINORS for non-randomized studies. Among RCTs, the
Schultz et al. trial [49] was an outlier (Jadad score = 0). This could be due to the fact that it is
only available in abstract form; there is therefore a lack of information on the study design.
The scores given to the other trials were satisfactory.
The strength of our study is that a standardized complex outcome score (IBS-SSS) was used
to measure the therapeutic effect. This score measures abdominal pain frequency and severity,
bloating, dissatisfaction with bowel habit and quality of life together on a 0–500 mm Visual
Analogue Scale (VAS). This scoring system provides information not only about symptoms,
but also about quality of life. A sufficient number of articles were found to carry out an accurate
statistical analysis, using this important outcome score. With this work, we proved not only the
positive effect of a low-FODMAP diet on IBS-SSS, but also its superiority to a high-FODMAP
standard IBS diet. Our meta-analysis is the first to provide unambiguous, high-level evidence
for the superiority of a low-FODMAP diet to a standard dietary approach in the improvement
of general symptoms and well-being among patients with IBS. These data suggest that the first-
line introduction of a low-FODMAP diet in the treatment of IBS could improve the therapeutic
effect on IBS symptoms and might decrease health care-related and societal costs [9].
There are some limitations to our study. First, we focused on the complex IBS-SSS, and due
to the lack of detailed published data, we did not perform a statistical analysis of the individual
symptoms in the symptom score. Therefore, it is not clear which of the five elements play a key
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role in the improvement of IBS symptom severity toward better personalization of this dietary
approach. The main reason was the lack of data and control groups, as well as the heterogene-
ity in the literature in measuring symptom severity (e.g. VAS and different types of Likert
scale). A uniform, consensus-based, well-comparable measurement of symptom severity (e.g.
IBS-SSS) is suggested for use in future studies. Second, we included not only full-text articles,
but also 4 short supplements [49–52] in our analysis, thus increasing the quantity of data on
control groups. Third, because of the lack of data in the different IBS subtypes, it is not clear
which subgroup experienced the greatest symptom improvement. Finally, the standard IBS
diet group was not homogeneous. The control diet always contained a significant number of
FODMAPs; however, only 2 out of 10 studies detailed exact food contents [8, 48]. Others prob-
ably used IBS dietary guidelines; thereafter, some differences were realized between contents,
thus potentially influencing our results.
To prove the effect of a low-FODMAP diet on bowel movement frequency in IBS patients
and to demonstrate which IBS subgroup could profit significantly from this diet, more double-
blind, randomized controlled trials should be conducted with the following standardized
parameters. Only patients fulfilling the most recent diagnostic criteria for IBS (Rome IV)
should be included in studies. A precise description of the contents of the diets studied is cru-
cial for an accurate analysis. It is highly recommended dietitians be involved in guiding
patients on diets to avoid significant differences within study groups and inadequate nutrient
intake. Patients should also be adequately monitored during trials to ensure their adherence to
a particular diet. Uniform outcome measures should be used to make studies scientifically
comparable. Except for measuring symptom severity on the VAS scale only, it is suggested that
a more detailed IBS-SSS be used in each subtype of the IBS patient group, which measures not
only the severity of the main symptoms, but also the quality of life. Yao et al. [55] discuss the
crucial points and difficulties of designing clinical trials in dietary interventions in patients
with functional gastrointestinal disorders.
Conclusion
This meta-analysis confirms that a diet low in fermentable oligosaccharides, disaccharides,
monosaccharides and polyols (FODMAP) significantly improves general symptoms and qual-
ity of life in patients with irritable bowel syndrome. Our analysis of the appropriate literature
data also confirms that a low-FODMAP diet is more effective than standard IBS dietary ther-
apy in patients diagnosed with IBS. However, a low-FODMAP diet raises certain issues, such
as the alteration of gut microbiota and inadequate nutrient intake without dietitian assistance.
The possible health advantages of a low-FODMAP diet—when it is effective—compared to
medical treatment require further evaluation. In consideration of its possible limitations and
based on findings from this meta-analysis, a low-FODMAP diet could be a potential first-line
and supplementary dietary therapeutic approach with the aid of a dietitian for patients with
irritable bowel syndrome to improve abdominal discomfort, abdominal pain, bloating and
quality of life. Because of the lack of published data, it is not possible to prove the effect of a
low-FODMAP diet on bowel movement frequency in IBS patients. It also remains unclear
which IBS subgroup could profit most from this diet. More randomized controlled trials are
called for to analyze these effects of dietary approaches.
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